Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-01
2006-08-01
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S268100, C546S269700, C546S270700
Reexamination Certificate
active
07084160
ABSTRACT:
The present invention provides compounds of formula Iand pharmaceutically acceptable salts thereof.The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
REFERENCES:
patent: 6040321 (2000-03-01), Kim et al.
patent: 6214852 (2001-04-01), Kim et al.
patent: 6262096 (2001-07-01), Kim et al.
patent: 2003/0069244 (2003-04-01), Leftheris et al.
Kim et al (2001): STN International CAPLUS database, Columbus (Ohio), Accession No.: 2001:521913.
Fan et al., Trend Pharcol. Sci., vol. 16, pp. 57-66 (1995).
Folkman, Nature Medicine, vol. 1, pp. 27-31 (1995).
Cullinan-Bove et al., Endocrinology, vol. 133, pp. 829-837 (1993).
Senger et al., Cancer and Metastasis Reviews, vol. 12, pp. 303-324 (1993).
DeVries et al., Science, vol. 255, pp. 989-991 (1992).
Terman et al., Biochem. Biophys. Res. Comm., vol. 187, pp. 1579-1586 (1992).
Jakeman et al., Endocrinology, vol. 133, pp. 848-859 (1993).
Koich et al., Breast Cancer Research and Treatment, vol. 36, pp. 139-155 (1995).
Connolly et al., J. Biol. Chem., vol. 264, pp. 20017-20024 (1989).
Bhide Rajeev S.
Borzilleri Robert M.
Cai Zhen-Wei
Qian Ligang
Tokarski John S.
Bristol--Myers Squibb Company
Korsen Elliott
Shameem Golam M. M.
LandOfFree
Heterocyclic inhibitors of kinases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic inhibitors of kinases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic inhibitors of kinases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3619129